Promising Potential of Lexicon Pharmaceuticals’ Sotagliflozin in Cardiometabolic Treatments: Analyst Recommends Buy Rating
I'm PortAI, I can summarize articles.
Analyst Joseph Pantginis from H.C. Wainwright has maintained a Buy rating on Lexicon Pharmaceuticals, with a price target of $4.00. This recommendation is based on the promising potential of sotagliflozin in treating cardiometabolic conditions, particularly highlighted by the ongoing Phase 3 SONATA-HCM trial. The drug shows efficacy in addressing adverse cardiac remodeling and has demonstrated significant reductions in major adverse cardiovascular events. Citi also reiterated a Buy rating with a $1.90 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments